表皮生长因子20号外显子插入突变的非小细胞肺癌靶向治疗药物—舒沃替尼  

The targeted therapeutic drug for non-small-cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations: sunvozertinib

作　　者：王晶[1] 赵紫楠[1] 金鹏飞[1] WANG Jing;ZHAO Zinan;JIN Pengfei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Bejing Hospital),Beijing 100730,China)

机构地区：[1]北京医院药学部,国家老年医学中心、中国医学科学院老年医学研究院、北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730

出　　处：《临床药物治疗杂志》2025年第1期35-39,共5页Clinical Medication Journal

摘　　要：舒沃替尼是用于治疗表皮生长因子(EGFR)20号外显子插入(Exon20ins)突变的局部晚期或转移性成人非小细胞肺癌(NSCLC)。Ⅰ期临床试验研究中,舒沃替尼(≥100 mg)在EGFR Exon20ins NSCLC患者中显示出抗肿瘤效果;300 mg剂量下,客观缓解率(ORR)为41.9%。在Ⅱ期临床试验中,舒沃替尼在接受过铂化疗的NSCLC和EGFR Exon20ins患者中也具有抗肿瘤疗效,ORR为60.8%。舒沃替尼具有良好的安全性和耐受性,主要不良反应以1~2级为主。本文从舒沃替尼的基本信息、作用机制、药动学、有效性、安全性及相互作用等方面进行总结,以期为临床治疗NSCLC提供参考。Sunvozertinib(DZD9008)is indicated for the treatment of adult patients with advanced or metastatic non-small cell lung cancer(NSCLC)harboring EGFR exon 20 insertion mutations(Exon20ins).In the PhaseⅠclinical trials,Sunvozertinib(at doses≥100 mg)demonstrated antitumor efficacy in patients with EGFR Exon20ins NSCLC.At 300 mg dose,the confirmed objective response rate(ORR)was 41.9%.In PhaseⅡclinical trials,Sunvozertinib also exhibited antitumor efficacy in patients with EGFR Exon20ins NSCLC who had previously received platinum-based chemotherapy,achieving an ORR of 60.8%.The majority of adverse reactions were grade 1 to grade 2,indicating favorable safety and tolerability.This article summarizes the basic information,mechanism of action,pharmacokinetics,efficacy,safety and drug interactions of Sunvozertinib,aiming to provide a reference for the clinical treatment of NSCLC.

关 键 词：舒沃替尼 非小细胞肺癌 表皮生长因子受体 20号外显子插入 

分 类 号：R979.19[医药卫生—药品]